These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Oldenburg B; Fijnheer R; van der Griend R; vanBerge-Henegouwen GP; Koningsberger JC Am J Gastroenterol; 2000 Oct; 95(10):2825-30. PubMed ID: 11051355 [TBL] [Abstract][Full Text] [Related]
25. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications. Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891 [TBL] [Abstract][Full Text] [Related]
26. Homocysteine in patients with inflammatory bowel diseases. Owczarek D; Cibor D; Sałapa K; Jurczyszyn A; Mach T Przegl Lek; 2014; 71(4):189-92. PubMed ID: 25141576 [TBL] [Abstract][Full Text] [Related]
27. Oral challenge with a methionine load in patients with inflammatory bowel disease: a better test to identify hyperhomocysteinemia. Zepeda-Gómez S; Montano-Loza A; Zapata-Colindres JC; Vargas-Vorackova F; Majluf-Cruz A; Uscanga L Inflamm Bowel Dis; 2008 Mar; 14(3):383-8. PubMed ID: 17924554 [TBL] [Abstract][Full Text] [Related]
28. Hyperhomocysteinemia in ulcerative colitis is related to folate levels. Zezos P; Papaioannou G; Nikolaidis N; Vasiliadis T; Giouleme O; Evgenidis N World J Gastroenterol; 2005 Oct; 11(38):6038-42. PubMed ID: 16273621 [TBL] [Abstract][Full Text] [Related]
29. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Koutroubakis IE; Sfiridaki A; Mouzas IA; Maladaki A; Kapsoritakis A; Roussomoustakaki M; Kouroumalis EA; Manousos ON Am J Gastroenterol; 2000 Jan; 95(1):190-4. PubMed ID: 10638581 [TBL] [Abstract][Full Text] [Related]
30. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Eikelboom JW; Lonn E; Genest J; Hankey G; Yusuf S Ann Intern Med; 1999 Sep; 131(5):363-75. PubMed ID: 10475890 [TBL] [Abstract][Full Text] [Related]
31. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Mahmud N; Molloy A; McPartlin J; Corbally R; Whitehead AS; Scott JM; Weir DG Gut; 1999 Sep; 45(3):389-94. PubMed ID: 10446107 [TBL] [Abstract][Full Text] [Related]
32. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Koutroubakis IE; Petinaki E; Anagnostopoulou E; Kritikos H; Mouzas IA; Kouroumalis EA; Manousos ON Dig Dis Sci; 1998 Nov; 43(11):2507-12. PubMed ID: 9824143 [TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Ray JG Arch Intern Med; 1998 Oct; 158(19):2101-6. PubMed ID: 9801176 [TBL] [Abstract][Full Text] [Related]
34. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Cattaneo M; Vecchi M; Zighetti ML; Saibeni S; Martinelli I; Omodei P; Mannucci PM; de Franchis R Thromb Haemost; 1998 Oct; 80(4):542-5. PubMed ID: 9798965 [TBL] [Abstract][Full Text] [Related]
36. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Liebman HA; Kashani N; Sutherland D; McGehee W; Kam AL Gastroenterology; 1998 Oct; 115(4):830-4. PubMed ID: 9753484 [TBL] [Abstract][Full Text] [Related]